Gnome Sciences, a molecular pathology and translational research services company, announced a significant advance in the fight against ALS (amyotrophic ...
The U.S. Food & Drug Administration (FDA) has awarded a Commissioner's National Priority Voucher (CNPV) for HERNEXEOS® (zongertinib tablets...
Phase 1a/1b study will evaluate NRM-823 as monotherapy and in combination with immune checkpoint inhibition in patients with locally-advanced or metastat...
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces clinical data for...
Moleculin Biotech, Inc., a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infecti...
N2OFF, Inc. a cleantech company investing in solar energy assets based on the RTB (Ready to Build) business model, recently announced the closing of the ...
IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune dise...
Australian patent strengthens global patent portfolio -bioAffinity Technologies, Inc. a biotechnology company advancing early-stage diagnostic...
Protaryx Medical, an innovative medical device company developing disruptive access solutions for minimally invasive left-heart procedures, announced tha...
-- XmAb819 is well-tolerated in heavily pretreated patients with advanced ccRCC -- -- 25% overall response rate (ORR) observed within the target dose ...
Acquisition focused on lead clinical-stage program ICT01 in acute myeloid leukemia, where data from the ongoing Phase I/II EVICTION trial showed high t...
Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response rate, sustai...
Collaboration with MSK’s Therapeutics Accelerator Program includes manufacturing, IND and clinical development support of the Bria-OTS+™ pl...
Adcytherix Raises EUR 105M Series A to Accelerate Breakthrough Antibody-Drug Conjugate Pipeline with Strategic Focus on Novel Payloads Financing led b...
© 2025 Biopharma Boardroom. All Rights Reserved.
